The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes.
In this study, we aimed to assess the factors associated with laboratory-defined aspirin resistance and the relationship of this laboratory-defined aspirin resistance with thrombolysis in myocardial infarction risk score, markers of cardiac necrosis, and inflammatory and thrombotic risk factors in patients with unstable angina or non-ST elevation myocardial infarction. Ninety-seven patients who were under aspirin therapy and hospitalized with unstable angina/non-ST elevation myocardial infarction were included in the study. Laboratory-defined aspirin sensitive and resistant groups were determined by platelet function analyzer; aspirin resistance was defined as collagen/epinephrine closure time less than 165 s. Laboratory-defined aspirin resistance was noted in 29 patients (29.9%), and non-ST elevation myocardial infarction was observed in 46 patients (47.4%). Patients in the group with laboratory-defined aspirin resistance had significantly higher thrombolysis in myocardial infarction risk scores (P < 0.001). When the details of cardiac myonecrosis markers were compared, baseline and follow-up creatine kinase-myocardial band and troponin I values were higher in laboratory-defined aspirin-resistant group. Multivariate analyses revealed that laboratory-defined aspirin resistance was an independent predictor of non-ST elevation myocardial infarction (P = 0.022). Laboratory-defined aspirin resistance is associated with non-ST elevation myocardial infarction, higher markers of cardiac necrosis and thrombolysis in myocardial infarction risk score in patients hospitalized with unstable angina/non-ST elevation myocardial infarction.
Acikel
Sadik
S
Faculty of Medicine, Department of Cardiology, Ministry of Health Dişkapi Yildirim Beyazit Research and Educational Hospital, Baskent University, Ankara, Turkey. sadik.acikel@tkd.org.tr
Yildirir
Aylin
A
Aydinalp
Alp
A
Bal
Ugur
U
Kaynar
Gamze
G
Ozin
Bulent
B
Muderrisoglu
Haldun
H
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D000368:Aged; D000789:Angina, Unstable / Q000097:blood / Q000453:epidemiology; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D015897:Comorbidity; D004351:Drug Resistance; D004562:Electrocardiography; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology / Q000209:etiology / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010979:Platelet Function Tests / Q000295:instrumentation; D012307:Risk Factors; D012720:Severity of Illness Index; D019851:Thrombophilia / Q000097:blood / Q000453:epidemiology
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin